Paper Details

  1. Home
  2. Paper Details

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.

Author: AlbackerLee A, BadveSunil, BalesCasey L, BallingerTarah J, BlayaMarcelo, CantorErica, ChenYu-Hsiang, ChitambarChristopher, CooperMaureen E, DailyKaren, FalksonCarla, GallagherChristopher, GrahamRobert, GreggJeffrey, HancockBradley A, HelftPaul, IsaacsClaudine, JiangGuanglong, KassemNawal, LynceFilipa C, MahtaniReshma, MillerKathy D, NandaRita, O'NeilBert, PaplomataElisavet, PavlickDean C, RadovichMilan, SchneiderBryan P, ShenFei, SolzakJeffrey P, StornioloAnna Maria V, ThompsonMichael A, WallingRadhika

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This phase II, multicenter trial (BRE12-158) compared genomically directed therapy with treatment of physician choice (TPC) in patients with triple-negative breast cancer (TNBC) who had residual disease after neoadjuvant chemotherapy (NAC). Patients with TNBC and residual disease after NAC are at high risk for recurrence.
Paper Details　
Original Abstract of the Article :
Patients with triple-negative breast cancer (TNBC) with residual disease after neoadjuvant chemotherapy (NAC) have high risk of recurrence with prior data suggesting improved outcomes with capecitabine. Targeted agents have demonstrated activity across multiple cancer types. BRE12-158 was a phase II...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.21.01657

データ提供：米国国立医学図書館（NLM）

Personalized Therapy for Triple-Negative Breast Cancer: A New Frontier

The fight against [研究分野: 癌] is a complex and evolving battleground. This study explores the potential of personalized therapy in treating triple-negative breast cancer (TNBC), a particularly aggressive form of the disease. The researchers conducted a phase II clinical trial to compare [研究目的: ゲノム指向治療 vs 医師選択治療] in patients with residual TNBC after neoadjuvant chemotherapy. [特筆すべき結果] The study aims to assess the efficacy of genomically directed therapy in improving outcomes for patients with TNBC.

Tailoring Treatment to the Individual: Personalized Therapy for TNBC

This study delves into the realm of personalized therapy for triple-negative breast cancer (TNBC). [研究結果] The researchers are evaluating the effectiveness of genomically directed therapy compared to standard treatment approaches. [社会的な意義] The study highlights the promise of personalized medicine in tailoring treatment strategies to the individual characteristics of each patient.

Hope for Patients with Triple-Negative Breast Cancer

This study offers hope for patients with triple-negative breast cancer (TNBC), a particularly challenging form of the disease. [健康的なベネフィット] Personalized therapy, tailored to individual genetic profiles, could potentially lead to more effective treatments and improved outcomes. [日常生活で気をつけるべきことや取り入れるべきこと] It's essential to stay informed about ongoing research and consult with healthcare professionals about available treatment options.

Dr.Camel's Conclusion

This study demonstrates the power of personalized medicine in the fight against cancer. Just as a camel navigates the desert with its unique adaptations, personalized therapy can adapt to the individual characteristics of each patient, potentially leading to more effective treatments and improved outcomes. The future of cancer treatment lies in recognizing the unique landscape of each patient's disease and developing tailored therapies for a more personalized and effective approach.

Date :
  1. Date Completed 2022-02-21
  2. Date Revised 2022-09-26
Further Info :

Pubmed ID

34910554

DOI: Digital Object Identifier

10.1200/JCO.21.01657

Related Literature

Article Analysis
・Effective treatment of breast cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.